BioSpace News Archive

Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announced today a corporate strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop poten

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the Raymond James 2020 Human Healthcare Innovation Conference on Thursday, June 18th, 2020, at 1:40 PM ET.

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs) Recruitment for the Edge and Evolve trials has been completed with 47 and 13 patients, respectively, and topline data is planned for the fourth quarter of 2020 Management expects to use the results for the two trials

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25 th EHA Annual Congress taking place June 11-21, 2020 . The presentation will be made available on the event’s web

Nanotronics today announced that it has developed and designed nHale™, a bi-level positive air pressure (BIPAP) device to support spontaneously breathing adults weighing over 30 kg.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that the first patient has been enrolled in the Phase 1b/2 RELEASE trial of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine, for the treatment of opioid withdrawal symptoms.

AMAG Pharmaceuticals, Inc. announced that Edward Myles, Chief Financial and Chief Operating Officer, is leaving the Company.

Raxia recently surveyed medical practices regarding their COVID-19 screening processes for in-person doctor appointments.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on June 18, 2020 at 10:20 a.m. ET.

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020